论文部分内容阅读
目的 探讨153 Sm -EDTMP、“云克”以及联合二者用于泌尿系肿瘤骨转移癌的止痛疗效。方法以 2 8例泌尿系恶性肿瘤并多发性骨转移患者为观察对象 ,其中153 m -EDTMP治疗组 1 0例、“云克”治疗组 9例、153 Sm -EDTMP和“云克”联合治疗组 9例 ,所有病例均随访观察 3个月。结果 153 Sm -EDTMP治疗组和“云克”治疗组对骨痛缓解总有效率分别为 80 %和 67% ,对骨病变有效率分别为 2 0 %和 1 1 % ,两组 2个指标比较均无显著性差异 (P >0 .0 5 )。而联合治疗组镇痛总有效率为 89% ,与前两组相比无显著性差异 (P >0 .0 5 ) ,对骨病变有效率为 44% ,与前两组比较有显著性差异 (P <0 .0 5 )。三组病例毒副作用均较小。结论 153 Sm -EDTMP和“云克”均对骨转移癌在镇痛方面有较好疗效 ,联合用药可能会进一步提高疗效 ,且毒副作用无明显增加
Objective To investigate the analgesic efficacy of 153 Sm-EDTMP, “Yunke” and their combination in the treatment of urinary tumors with bone metastases. Methods Twenty-eight patients with urinary malignancies and multiple bone metastases were enrolled in this study. Among them 153 cases were treated with 153 m -EDTMP, 9 cases with “Yunke” treatment and 153 Sm-EDTMP combined with “Yunke” Group 9 cases, all cases were followed up for 3 months. Results The total effective rates of bone pain relief in 153 Sm-EDTMP group and Yunke group were 80% and 67%, respectively, and the effective rates of bone lesions were 20% and 11% respectively. The two indexes of two groups were compared No significant difference (P> 0.05). The combined treatment group, the total effective rate of analgesia was 89%, compared with the previous two groups no significant difference (P> 0.05), the effective rate of bone lesions was 44%, compared with the previous two groups were significantly different (P <0. 05). Three cases of side effects are small. Conclusion Both 153 Sm-EDTMP and “Yunke” have good curative effect on the analgesic of bone metastases, and the combined treatment may further improve the curative effect with no obvious increase of toxic and side effects